MIA STANCIL: Open Payments
NPI 1649902156 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,236 in 57 payments from 18 companies in 2025. Trend: 2023 $385 · 2024 $1,001 · 2025 $1,236
Food & beverage: $1,236
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $169 |
| Dexcom, Inc. | 2 | $149 |
| AstraZeneca Pharmaceuticals LP | 6 | $144 |
| Lilly USA, LLC | 8 | $136 |
| Novartis Pharmaceuticals Corporation | 5 | $117 |
| SANOFI-AVENTIS U.S. LLC | 5 | $98 |
| Amgen Inc. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $53 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| Exact Sciences Corporation | 2 | $43 |
Products named: DEXCOM G7 GSS (161), LEQVIO, MOUNJARO, TZIELD, Wegovy, FARXIGA, Kerendia, Ozempic.
Industry payments across GA — which companies pay providers there.
